stockrowCorcept Therapeutics Incorporated (CORT) vs Spyre Therapeutics, Inc. (SYRE)
- Corcept Therapeutics Incorporated CORT 72.94 +1.83%
- Spyre Therapeutics, Inc. SYRE 103.23 +6.87%
Corcept Therapeutics Incorporated and Spyre Therapeutics, Inc. are both Biotechnology companies. Spyre Therapeutics, Inc. is the larger, with a market value of $9.2B against $7.8B — 1.2× the size. Spyre Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Corcept Therapeutics Incorporated trades at 47.5×. Corcept Therapeutics Incorporated grew revenue faster over the last twelve months: 30.0% against −81.8%. Corcept Therapeutics Incorporated has the higher net margin (16.5% vs 0.00%) and the higher return on invested capital (15.0% vs 0.00%). Across the 18 metrics below, Corcept Therapeutics Incorporated leads on 14 and Spyre Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | CORT | SYRE | Biotechnology median |
|---|---|---|---|
| Gross margin | 98.54% | 100.00% | 65.16% |
| Operating margin | 11.51% | 0.00% | 0.00% |
| Net margin | 16.54% | 0.00% | 0.00% |
| Free cash flow margin | 20.20% | 0.00% | 0.00% |
| Return on equity | 21.74% | (41.15%) | (50.12%) |
| Return on assets | 17.16% | (30.89%) | (45.60%) |
| Return on invested capital | 14.97% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack